Vigil NeuroscienceVIGL
About: Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
Employees: 66
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
2% less funds holding
Funds holding: 52 [Q3] → 51 (-1) [Q4]
14.61% less ownership
Funds ownership: 69.93% [Q3] → 55.32% (-14.61%) [Q4]
59% less capital invested
Capital invested by funds: $94.5M [Q3] → $38.4M (-$56M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 351 met price target | 706%upside $17 | Buy Reiterated | 23 Jan 2025 |
Financial journalist opinion
Based on 3 articles about VIGL published over the past 30 days
